Open access peer-reviewed chapter

Treatment Decisions and Survival in Ovarian Cancer

Written By

Hugo de Seabra Martins Nunes, Alexandra Mayer, Ana Francisca Jorge, Teresa Margarida Cunha, Ana Opinião, António Guimarães and Fátima Vaz

Submitted: July 18th, 2017 Reviewed: February 20th, 2018 Published: March 28th, 2018

DOI: 10.5772/intechopen.75718

Chapter metrics overview

1,160 Chapter Downloads

View Full Metrics


Objective: to review the most recent data on the impact of the primary treatment and individual factors on ovarian cancer patient survival and to study it in a real world population. Methods/materials: retrospective analysis of 147 consecutive ovarian cancer patients treated with platin-based chemotherapy, either after primary debulking surgery (PDS) (n = 94, 64%) or as neoadjuvant (NACT) treatment (53, 36%). Results: NACT patients were older (64.3 vs. 58.2 years), with radiologically unresectable disease (74%) and/or comorbidities (26%). Fifty-five percent of pts. submitted to PDS were staged III/IV. Serous carcinomas were equally distributed (PDS-57% vs. NACT-60%) but endometrioid (20 vs. 4%) and carcinomas not otherwise specified (6 vs. 30%) were more frequently diagnosed in the PDS and NACT group, respectively. Genetic diagnosis (24.4%): 11 BRCA1/2 and 1 RAD51C carriers identified. Residual disease after surgery was the only significant prognostic factor for both relapse (HR = 2267) and death (HR = 1847). Primary debulking surgery was associated with a significantly better PFS (HR = 0.541; p = 0.012) and with a trend to a better OS (HR = 0.714; p = 0.296). For pts. with III/IV disease OS was significantly superior in the PDS group. Conclusion: residual disease was the only significant prognostic factor. Primary surgery was associated with a significantly better PFS. The difference in OS was significant in stage III/IV patients. This reinforces the importance of maximal cytoreduction.


  • epithelial ovarian cancer
  • neoadjuvant therapy
  • primary surgery

1. Introduction

Ovarian cancer (OC) is the most lethal gynaecological malignancy in developed countries, with over 225.000 new cases and more than 140.000 deaths every year worldwide [1]. Epithelial OC is currently divided into seven main subtypes: serous, endometrioid, clear cell, mucinous, transitional cell, mixed and undifferentiated and unclassified OC [2]. Due to inadequate screening and a lack of early clinical symptoms, 70% of women with OC present with advanced disease, associated with high morbidity and mortality [1, 3]. The standard of care for OC treatment comprises maximal cytoreductive resection aiming to remove all visible tumour tissue, followed by platinum-taxane chemotherapy [4]. However, most patients relapse within the first 5 years after diagnosis, with a median progression-free survival (PFS) of 11 to 18 months and a median overall survival (OS) of 24 to 38 months [5, 6]. Data from the EUROCARE show a 5-year age-standardised relative survival of 37.6% [7]. Data from the National Cancer Institute show a 5-year survival of 46.2% [8].

Many OC patient characteristics are associated with survival, like stage [9, 10], histology [10, 11, 12, 13, 14], residual disease and debulking status after cytoreductive surgery [10, 12, 14, 15], type of chemotherapy [6, 10, 13, 16] and BRCA status [17, 18]. Maximal surgery, even when total absence of residual disease cannot be obtained, seems to relate to survival advantage [19]. The expertise of the surgical team is important in providing optimal cytoreduction without compromising post-operative morbidity [20].

A subgroup of OC patients is found to have surgically unresectable cancer and prediction criteria for suboptimal cytoreduction are important in treatment decisions. Studies using computed tomography (CT) suggested that the presence of an omental cake extending to the spleen, a diaphragm coated by tumour or lesions >2 cm in the suprarenal, para-aortic lymph-nodes and porta hepatis, among others [21], were predictors of unresectable disease. Other features predicting the outcome of cytoreduction correspond to traditionally difficult anatomic locations, such as extensive upper abdominal disease [22]. Recently, the Society of Gynecologic Oncology and the American Society of Clinical Oncology published the latest guidelines on neoadjuvant chemotherapy (NACT), stating the predictors of suboptimal cytoreduction. These include radiological predictors, such as retroperitoneal lymph-nodes above the renal hilum >1 cm, diffuse small bowel adhesions or thickening, small bowel mesentery lesions >1 cm, root of the superior mesenteric artery lesions >1 cm, perisplenic lesions >1 cm, lesser sac lesions >1 cm, and ascites on at least two-thirds of CT scan slices; and clinical predictors such as age ≥ 60 years and CA-125 ≥ 500 U/mL [23].

Interval debulking surgery (IDS) after NACT for patients with unresectable disease criteria is still controversial. A meta-analysis [24] suggested that NACT was associated with a worse outcome, but in 2010 a study concluded that it was not inferior to primary debulking surgery (PDS) in bulky stage IIIC or IV OC [25]. Moreover, it was associated to significantly lower adverse effects, such as postoperative infections, venous complications, fistula and haemorrhage, as well as lower postoperative mortality rates [25, 26, 27]. Other studies, such as the SCORPION and the JCOG0602 trials, seem to confirm these findings [23]. Some phase III trials suggested that NACT would also lead to improved quality of life [28, 29, 30]. Preoperative predictors for complete cytoreduction and outcomes from NACT are needed and subject of research [31].

The decision of treating advanced OC patients with NACT became more frequent [32], but there are still unsolved issues. Staging is surgical and based on laparotomy findings. Residual disease after surgery is a major prognostic factor for survival [14, 25] and visual evaluation by the surgeon is critical to conclude about intra-abdominal tumour spread. Whether the surgeons’ statement of complete tumour resection is equal in primary surgery and in IDS remains unclear. Microscopically carcinomatous areas may have a benign visual appearance after NACT [33] interfering with the visual evaluation of tumour extension and potentially leading to incomplete cytoreduction. Also, the possibility that NACT may induce platinum resistance [34, 35] remains unclear. A recent study revealed that although the proportion of platinum-resistant recurrence after NACT and IDS was superior, this difference was not significant. A significant difference was only observed when women who had a recurrence were retreated with platinum-based chemotherapy [36].

The highest risk associated with NACT may be that patients with significant side effects and refractory disease will lose the opportunity for debulking surgery [37], although it has been suggested that these patients have a poor prognosis and should be encouraged to participate in clinical trials or to discontinue active cancer therapy [23]. Another limitation of NACT is the insufficient data supporting the use of intraperitoneal (IP)/intravenous (IV) chemotherapy as adjuvant treatment after NACT [23]. Recent results from the OV21/PETROC trial seem to support that a carboplatin-based IP regimen, after NACT and debulking surgery, is well tolerated and associated with a higher PFS compared to IV therapy (immature data) [38].

Besides patient characteristics, survival depends on treatment decisions and questions remain about the reproducibility of study data in routine clinical practice. We tried to review the most recent data on the primary treatment of OC and the factors that have impact on the survival of these patients. Therefore, our objective was to characterise a consecutive series of OC patients treated in our centre and to analyse the effect of patient variables and decision criteria on efficacy outcomes for patients treated with either PDS or primary NACT.


2. Material and methods

This study is a retrospective analysis. It includes all patients with epithelial OC observed in the Gynaecological Oncology multidisciplinary group of our centre and registered in the South Portuguese Cancer Registry (ROR-Sul), between January 2006 and December 2011. Medical records were reviewed, and demographic, clinical, surgical, pathologic, molecular and follow-up information obtained. Optimal cytoreduction was defined as no macroscopic residual disease at the end of surgery. Pathology data were collected from the pathology report after citoreductive surgery. The chemotherapy regimen used was the doublet of carboplatin (AUC = 6) and paclitaxel (175 mg/m2 of body surface). Progression data were obtained from clinical notes: most were confirmed by CT scan and CA125 measurement criteria. In less than 5% of cases, progression was assumed by CA125 measurement and clinical examination. Information concerning molecular testing was obtained from patients previously counselled and given informed consent through procedures and forms approved by the Ethics Committee.

2.1. Statistics

Statistical analysis was performed with IBM SPSS Statistics software (version 23). Continuous data (presented as the means ± SD) that were normally distributed were analysed using Student’s t-test, while data that were not normally distributed were analysed using the Mann–Whitney U test. The Pearson’s exact chi-square or Fisher’s exact test were used to compare the proportions between groups. Progression-free survival was defined as the time interval between the end of primary treatment and the date of progression. If there was no documented recurrence, PFS was calculated from the end of primary treatment to the date of last follow-up or death. Platinum-resistant relapse was defined as recurrence within 6 months of primary treatment. Overall survival was defined as the time interval between date of diagnosis and date of death or last follow-up. Progression free survival and OS were analysed by the log-rank test and the results were expressed as Kaplan–Meier plots. A Cox proportional hazards model was estimated to assess the impact of different prognostic variables on survival. A p value <0.05 was defined as statistically significant.


3. Results


3.1. Cases

Two hundred and fifty-seven patients were registered in the ROR-Sul database and 147 (58%) of those received systemic treatment and were included in this analysis. Excluded patients either were not submitted to surgery or chemotherapy in our centre, died without any specific treatment, had non-eligible neoplasia after surgery (3 mucinous adenocarcinomas of the appendix) or were diagnosed with early stage disease with low-risk features (Figure 1).

Figure 1.

Study design. OC: Ovarian cancer; PDS: Primary debulking surgery; NACT: Neoadjuvant chemotherapy; IDS: Interval debulking surgery.

Demographic and clinical characteristics are summarised in Table 1. All 147 patients were treated with platin-based chemotherapy: either following primary surgery (n = 94, 64%) or in the neoadjuvant setting (n = 53, 36%). The mean age at diagnosis was 60.4 years (25–89; IC95% = [58.4–62.4]); patients in NACT group were older (64.3 vs. 58.2; p = 0.002) and we did not observe age differences between advanced versus non-advanced stages, different histologic subtypes or between platinum-resistant versus platinum-sensitive patients (p = 0.318; p = 0.108; p = 0.774, respectively). More cases of advanced disease were treated with NACT (6% stages IIIB, 83% IIIC-IV) as compared with primary surgery (27% stages IA-IC, 36% IIA-IIIB, 37% IIIC-IV). The median number of chemotherapy cycles was superior in the NACT group (8 vs. 6; p = 0.000). Macroscopic residual disease after debulking surgery (PDS or IDS) was present in 46% of all cases (IC95% = [37%; 54%]) and was not associated with the treatment modality (Pearson X2 = 0.001; p = 1.000). Most cases were serous, endometrioid or carcinomas not otherwise specified (NOS) (58.5, 14.3 and 15%, respectively); 9 patients (6%) had cancers with mucinous/clear cell histology. The proportion of serous carcinomas was similar between groups. In the PDS group, a significantly higher proportion of endometrioid tumours was observed (20 vs. 2%; p = 0.021) while carcinomas NOS were more frequent in the NACT group (16 vs. 6%; p = 0.021). Thirty-six patients (24.4%) had information of molecular testing: 23 in the PDS (7 BRCA carriers) and 13 in the NACT (4 BRCA carriers and 1 RAD51C carrier) groups.

PDS (N = 94)NACT–IDS (N = 53)P
Age (mean, years)58 (±12)64 (±10)0.002
Histology [N(%)]
Serous54 (57.4)32 (60.4)0.021
Endometrioid19 (20.4)2 (3.8)
Mucinous3 (3.2)1 (1.9)
Clear cell4 (4.3)1 (1.9)
Mixed2 (2.1)0 (0)
Poorly differentiated6 (6.4)1 (1.9)
Carcinoma NOS6 (6.4)16 (30.2)
FIGO Stage [N(%)]
IA-IC25 (26.6)0.000
IIA-IIC17 (18.1)
IIIA5 (5.3)
IIIB12 (12.8)3 (5.7)
IIIC21 (22.3)15 (28.3)
IV14 (14.9)29 (54.7)
Unknown6 (11.3)
Nr of cycles (median)6 (±1.3)8 (±2.7)0.000
Residual disease after debulking surgery [N(%)]60 (64)29 (55)1.000

Table 1.

Demographic and clinical characteristics of the study population. PDS: Primary debulking surgery; NACT-IDS: Neoadjuvant chemotherapy and interval debulking surgery; NOS: Not otherwise specified; Values for continuous measurements are means, unless otherwise specified; FIGO: International Federation of Gynecology and Obstetrics.


3.2. Treatment decision

The decision for NACT was due mainly to radiological criteria: implants >2 cm outside the pelvis (18 pts; 34%), lymphadenopathies above renal hilum (12 pts; 23%), subcapsular or Parenchymal liver metastasis (8; 15%) or pre-sacred retroperitoneal disease (1 pt; 2%). In 14 pts (26%), comorbidities that contraindicated upfront surgery were also considered in the decision for NACT.


3.3. Efficacy analysis

For the total cohort, the median PFS and OS were 13.4 (IC95%= [9,3-17,5]) and 44.0 (IC95% = [29.7–58.3]) months, respectively. In the PDS group, PFS was significantly superior (23.4 vs. 13.8 months; p = 0.010), even when restricting analysis to advanced stages (21.4 vs. 12.5 months; p = 0.040). Patients with no macroscopic residual disease after debulking surgery had superior PFS (27.0 vs. 14.0 months; p = 0.000).

For patients treated with PDS, OS was significantly superior (48.4 vs. 30.9 months; p = 0.001), even when restricting the analysis to advanced stages (44.4 vs. 28.2 months; p = 0.014) (Figure 2).

Figure 2.

Kaplan–Meier survival curves showing the PFS and OS rates of patients in the NACT/IDS vs. PDS groups (only advanced stages) (7.3 vs. 13.4 months; p = 0.010 and 21.0 vs. 55.1 months; p = 0.001, respectively).

Patients with no macroscopic residual disease after debulking surgery had superior OS (52.7 vs. 36.0 months; p = 0.002) (Figure 3), as well as those with non-advanced stage disease (52.5 vs. 37.1 months; p = 0.009). Moreover, patients with platinum-sensitive relapse (>6 months) had significantly superior OS (56.0 vs. 12.3 months; p = 0.000) (Figure 4), as compared to platinum resistant patients.

Figure 3.

Kaplan–Meier survival curves showing the PFS and OS rates of patients with vs. without macroscopic residual disease after debulking surgery (PFS: 9.9 vs. 25.1 months, p = 0.000; as it did not fall below 50% at the time of the analysis, it is not possible to estimate median OS, p = 0.002).

Figure 4.

Kaplan–Meier survival curves showing OS rates of patients with platinum-sensitive vs. platinum-resistant relapse after primary treatment (63.0 vs. 8.0 months, p = 0.000).

The Cox proportional hazards model (Table 2) allowed estimating the impact in survival of factors such as age at diagnosis, histology, stage, platinum free interval, residual disease after debulking surgery and therapeutic modality. Adjusting for these variables, the only statistically significant prognostic factor for both relapse and death was the presence of macroscopic residual disease after surgery, with more than 2-fold higher risk of relapse (HR = 2267; p = 0.000) and 80% higher risk of death (HR = 1847; p = 0.036). Primary debulking surgery was associated to a significantly better outcome, but only in terms of PFS (HR = 0.541; p = 0.012), with no significant gain in OS compared to NACT, although there is a trend to a better outcome (HR = 0.714; p = 0.296). Other factors, such as age, histology or advanced stage did not have a significant effect on relapse. Platinum-resistant disease was associated with a 9-fold higher risk of death (HR = 8964; p = 0.000). There is a trend towards a worse prognosis of advanced stage disease (HR = 1293; p = 0.468) and towards a better outcome of serous histology (HR = 0.847; p = 0.560).

CoefficientSEPHR (95% CI)CoefficientSEPHR (95% CI)
Age0.0210.0120.0971021 (0.996–1046)0.0040.0080.5591004 (0.990–1020)
Serous histology (vs nonserous)−0.1660.2850.5600.847 (0.484–1481)0.3230.1940.0961381 (0.944–2020)
Advanced stage (stage III-IV vs. I-II)0.2570.3540.4681293 (0.646–2590)−0.3150.2430.1950.730 (0.453–1176)
Residual disease0.6030.2930.0361847 (1040–3278)0.8180.2190.0002267 (1504–3416)
PDS (vs NACT)−0.3370.3220.2960.714 (0.380–1344)−0.6150.2440.0120.541 (0.335–0.873)
Platinum resistant disease21930.3000.0008964 (4976–16.147)

Table 2.

Multivariate Cox regression model. OS: overall survival; PFS: progression-free survival; SE: standard error; HR: hazard ratio; CI: confidence interval; PDS (vs NACT): primary debulking surgery (vs neoadjuvant chemotherapy).

Ninety seven percent (97%) of patients relapsed and almost 1/3 of these (46 pts) had platinum-resistant disease (31%; IC95% = [23%; 39%]). The treatment strategy (NACT vs. PDS) and residual disease after debulking surgery were not associated with the occurrence of relapse (Pearson X2 = 2318 and p = 0.297; Pearson X2 = 0.708 and p = 0.625, respectively).

At the time of this analysis, all BRCA carriers (7/7) in the PDS and 75% of BRCA carriers in the NACT (3/4) group were alive as compared to 54 and 36% of patients with unknown BRCA status, respectively.


4. Discussion

Between 2006 and 2011, NACT was decided as primary approach for advanced OC, mostly for patients with radiologically determined unresectable disease and for older patients with comorbidities. Independently of the therapeutic modality, non-advanced stage at diagnosis and absence of residual disease after surgery were associated with progression free survival. Adjusting for age at diagnosis, histology, stage, platinum free interval, residual disease after surgery and therapeutic modality (either NACT or PDS), the only statistically significant prognostic factor for both relapse and death was the presence of macroscopic residual disease after surgery. Primary debulking surgery was associated with a significantly better outcome only in terms of PFS, although a trend to a better OS was also observed. When analysis was restricted to stages III and IV OS was significantly superior in the PDS group, as compared with the NACT group. BRCA status was known for a small proportion of patients in both groups, which limits statistical analysis and conclusions. However, it’s interesting to note that all known BRCA carriers in the PDS group were alive at the time of this analysis, compared to only 75% after NACT-IDS. That happens for unknown BRCA status patients as well, but with a smaller difference between groups (54 vs. 36%). Recent observations suggest a selection of tumour cell clones without somatic loss of heterozygosity (LOH) for the wild-type allele of BRCA genes, during neoadjuvant therapy [39].

Patients treated with PDS had better outcome in terms of PFS. This is not unexpected since this group included patients with less advanced disease, but suggests that the cytotoxic treatment before primary surgery in the NACT group could not counteract the bad prognosis associated with advanced stage. This was observed even if patients in the NACT group received a higher number of chemotherapy cycles (8 vs. 6; p = 0.000). Some authors have expressed concern about the selection of resistant clones in patients submitted to NACT [34, 35, 36] but we did not observe an association between the platinum free interval and the chosen treatment approach (Pearson X2 = 3955 and p = 0.058). Patients with platinum-sensitive relapse (>6 months) had significantly superior OS (56.0 vs. 12.3 months; p = 0.000), as compared to platinum resistant patients. This was confirmed in the multivariate survival analysis, with Cox model showing that platinum-resistant disease was associated with a 9-fold higher risk of death (HR = 8964; p = 0.000). These findings should be carefully interpreted, since further lines of treatment widely vary between platinum-sensitive and platinum-resistant populations. There is evidence that longer platinum-chemotherapy-free interval is associated with better survival (especially PFS after further lines of treatment) [40], but although the platinum-free interval is defined as the period of time from the last date of platinum dose until progressive disease is documented, it does not take into account how progression is defined (CA125 alone, radiological and symptomatic recurrence) [41].

The PDS group had a significantly higher number of patients with endometrioid histology. This factor and more advanced cases in the NACT group, may have contributed to the better outcomes in patients submitted to upfront surgery. The higher proportion of carcinoma NOS in NACT group (16 vs. 6%; p = 0.021) is a limitation of our study, since consecutive pathology review was not done. However, this finding is not unexpected in pathology reports of surgical specimens after NACT.

We did not observe an improvement of optimal debulking rates with NACT, as macroscopic residual disease after debulking surgery (PDS or IDS) was not associated with the treatment strategy (Pearson X2 = 0.001; p = 1.000). In the 2010 EORTC-NCIC trial, no gross residual tumour after PDS was achieved in 19% of patients and after IDS in 51% of patients [25]. Progression-free survival and OS for both arms were 12 and 30 months, respectively. In our cohort, cytoreduction was higher (36%) in the PDS group, as well as PFS and OS (13.4 and 55.1 months, respectively). Cytoreduction rate for our NACT group (45%) was closer to the rate described in the EORTC trial but our observations for PFS and OS were lower (7.3 and 21.0 months, respectively). Besides the expected differences between a randomised trial and an observational study, stage IV patients were well-balanced between arms in the EORTC trial but predominated in the NACT group (55 vs. 15%) of our study. In the CHORUS trial the complete cytoreduction rate was inferior to the one in our cohort, both in PDS and NACT groups (15 vs. 35%) but PFS and OS outcomes with NACT were better (10 and 23 months, respectively) than with PDS (12 and 25 months, respectively) [42]. However, a recent observational trial [32] showed NACT to be inferior to PDS in stage IIIC but superior in stage IV. It is important to remember that, for this analysis, we considered complete cytoreduction as the absence of macroscopic residual disease, even if, this was not the case for other studies [25, 32, 42].

Although retrospective, our study reflects how decisional criteria for both modalities were applied in a group of consecutive, non-selected OC patients. Statistical methodologies were selected according to the retrospective nature of the study: univariate analysis first identified factors influencing the outcomes of these patients (other than primary treatment); these factors were then integrated in the multivariate analysis (Cox regression model), to ascertain the efficacy of each strategy, adjusting to variables previously identified as an influence to prognosis. Limitations to this study are possible selection and recall bias, as well as unknown confounding variables that may have a negative impact on the accuracy of the results. One example is the limited accuracy in determining performance status and comorbidities as criteria for the decision of upfront treatment, although notes from multidisciplinary meetings were carefully reviewed. As for the assessment of residual disease after debulking surgery, heterogeneity was observed due to changing criteria for the classification of ideal resection during the period covered by our study.

In conclusion, the only significant prognostic factor for both relapse and death was the presence of macroscopic residual disease after surgery, which enhances the importance of maximal cytoreduction in the primary treatment. As for the influence of treatment modality on outcomes, PDS was associated to a significantly better PFS and a non-significant trend to a better OS. Other factors, such as age, histology or advanced stage did not have a significant effect on relapse. Our findings are in agreement with other studies [19, 20, 25, 32, 42, 43] about the impact of optimal debulking surgery in survival of OC patients. This is observed whether complete debulking is attained with easily resectable disease or extensive surgery. It has also been shown that the impact of potentially negative biologic factors such as grade and histology can be overcome by surgical debulking [43]. This is why surgical expertise plus supportive management (antibiotics, blood banking, and intensive care) should parallel the development of better systemic therapies.


  1. 1. Jemal A, Bray F, Ferlay J. Global cancer statistics: 2011. CA: a Cancer Journal for Clinicians. 2011;61(2):69-90
  2. 2. Kurman R, Carcangiu M, Herrington C, Young R, Curto G, Longo G, et al. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Lyon, France: IARC WHO Classif Tumours; 2014
  3. 3. Cannistra SA. Cancer of the ovary. The New England Journal of Medicine. 2004;351:2519-2529
  4. 4. Ledermann J, Raja F, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013;24(Suppl. 6):vi24-vi32
  5. 5. Piccart M, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of Cisplatin-paclitaxel versus Cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: Three-year results. Journal of the National Cancer Institute. 2000;92(9):699-708
  6. 6. Mcguire W, Hoskins W, Brady M, Kucera P, Partridge E, Look K, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. The New England Journal of Medicine. 1996;334(1):1-6
  7. 7. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: Results of EUROCARE-5 - a population-based study. The Lancet Oncology. 2016;15(1):23-34
  8. 8. Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Altekruse S, et al. SEER Cancer Statistics Review. Bethesda, MD: Natl Cancer Institute; 1975-2013
  9. 9. Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ, Curto F, et al. Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstetrics and Gynecology. 1999;93(1):21-24
  10. 10. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The gynecologic oncology group experience. Journal of Clinical Oncology. 1991;9(7):1138-1150
  11. 11. Halperin R, Zehavi S, Langer R, Hadas E, Bukovsky I, Schneider D, et al. Primary peritoneal serous papillary carcinoma: A new epidemiologic trend? A matched-case comparison with ovarian serous papillary cancer. International Journal of Gynecological Cancer. 2001;11(5):403-408
  12. 12. Hoskins W, Bundy B, Thigpen J, Omura G, Curto G, Longo H, et al. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A gynecologic oncology group study. Gynecologic Oncology. 1992;47(2):159-166
  13. 13. Marszalek A, Alran S, Scholl S, Fourchotte V, Plancher C, Rosty C, et al. Outcome in advanced ovarian cancer following an appropriate and comprehensive effort at upfront cytoreduction: A twenty-year experience in a single cancer institute. International Journal of Surgical Oncology. 2010;2010:214919
  14. 14. Winter WE, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, et al. Prognostic factors for stage III epithelial ovarian cancer: A gynecologic oncology group study. Journal of Clinical Oncology. 2007;25(24):3621-3627
  15. 15. Gerestein CG, Eijkemans MJC, De Jong D, Van Der Burg MEL, Dykgraaf RHM, Kooi GS, et al. The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma. BJOG: An International Journal of Obstetrics & Gynaecology. 2009;116(3):372-380
  16. 16. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. Obstetrical & Gynecological Survey. 2012;67(5):289-290
  17. 17. Bolton KL. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. Journal of the American Medical Association. 2012;307(4):382-390
  18. 18. Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: A report from the Australian ovarian cancer study group. Journal of Clinical Oncology. 2012;30(21):2654-2663
  19. 19. Wallace S, Kumar A, Mc Gree M, Weaver A, Mariani A, Langstraat C, et al. Efforts at maximal cytoreduction improve survival in ovarian cancer patients, even when complete gross resection is not feasible. Gynecologic Oncology. 2017;145(1):21-26
  20. 20. Giede KC, Kieser K, Dodge J, Rosen B, Curto G, Longo F, et al. Who should operate on patients with ovarian cancer? An evidence-based review. Gynecologic Oncology. 2005;99(2):447-461
  21. 21. Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. Journal of Clinical Oncology. 1993;11(1):166-172
  22. 22. Bristow R, Duska L, Lambrou N, Fishman E, O’Neill M, Trimble E, et al. A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer. 2000;89:1532-1540
  23. 23. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of clinical oncology clinical practice guideline. Journal of Clinical Oncology. 2016;34(28):3460-3473
  24. 24. Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer : A meta-analysis. Gynecologic Oncology. 2006;103:1070-1076
  25. 25. Vergote I, Tropé C, Amant F, Kristensen G, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. The New England Journal of Medicine. 2010;363:943-953
  26. 26. Van der Burg M, Van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced apithelial ovarian cancer. The New England Journal of Medicine. 1995;332(10)
  27. 27. Rose P, Nerenstone S, Brady M, Clarke-pearson D, Olt G, Rubin S, et al. Secondary surgical Cytoreduction for advanced ovarian carcinoma. The New England Journal of Medicine. 2004;351:2489-2497
  28. 28. Rustin GJS, Van Der Burg MEL, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): A randomised trial. Lancet. 2010;376(9747):1155-1163
  29. 29. Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D, Mackey D, et al. Quality-of-life comparisons in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: A gynecologic oncology group study. Journal of Clinical Oncology. 2005;23(24):5605-5612
  30. 30. Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, et al. Quality of life in ovarian cancer patients: Comparison of paclitaxel plus cisplatin, with cyclophosphamide plus cisplatin in a randomized study. Journal of Clinical Oncology. 2004;22(22):4595-4603
  31. 31. Baek M-H, Lee S-W, Park J-Y, Rhim CC, Kim D-Y, Suh D-S, et al. Preoperative predictive factors for complete cytoreduction and survival outcome in epithelial ovarian, tubal, and peritoneal cancer after neoadjuvant chemotherapy. International Journal of Gynecological Cancer. 2017;27(3):420-429
  32. 32. Meyer LA, Cronin AM, Sun CC, Bixel K, Bookman MA, Cristea MC, et al. Use and effectiveness of neoadjuvant chemotherapy for treatment of ovarian cancer. Journal of Clinical Oncology. 2016 Nov 10;34(32):3854-3863
  33. 33. Hynninen J, Lavonius M, Oksa S, Grénman S, Carpén O, Auranen A, et al. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecologic Oncology. 2013;128(2):229-232
  34. 34. Matsuo K, Eno ML, Im DD, Rosenshein NB, Curto H, Longo H, et al. Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. Archives of Gynecology and Obstetrics. 2010;281(2):325-328
  35. 35. Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecologic Oncology. 2012;124(1):10-14
  36. 36. Rauh-Hain JA, Nitschmann CC, Worley MJ, Bradford LS, Berkowitz RS, Schorge JO, et al. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. Gynecologic Oncology. 2013;129(1):63-68
  37. 37. Sato S, Itamochi H. Neoadjuvant chemotherapy in advanced ovarian cancer: Latest results and place in therapy. Therapeutic Advances in Medical Oncology. 2014;6(6):293-304
  38. 38. Mackay H, Gallagher C, Parulekar W, Ledermann J, Armstrong D, Gourley C, et al. OV21/PETROC: A randomized gynecologic cancer intergroup (GCIG) phase II study of intraperitoneal (IP) versus intravenous (IV) chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer (EOC). Journal of Clinical Oncology. 2016;34 (suppl; abstr LBA5503)
  39. 39. Gorodnova TV, Sokolenko AP, Ivantsov AO, Iyevleva AG, Suspitsin EN, Aleksakhina SN, et al. High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation. Cancer Letters. 2015;369(2):363-367
  40. 40. Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, et al. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Annals of Oncology. 2013;24(4):937-943
  41. 41. Pujade-Lauraine E. How to approach patients in relapse. Annals of Oncology. 2012;23(Suppl. 10):23-26
  42. 42. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;6736(14):1-9
  43. 43. du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J, et al. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: By the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzin. Cancer. 2009;115(6):1234-1244

Written By

Hugo de Seabra Martins Nunes, Alexandra Mayer, Ana Francisca Jorge, Teresa Margarida Cunha, Ana Opinião, António Guimarães and Fátima Vaz

Submitted: July 18th, 2017 Reviewed: February 20th, 2018 Published: March 28th, 2018